Clinical Trial: MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07823127) titled 'MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)' on Aug. 12.

Brief Summary: This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in pregnant women with intrahepatic cholestasis of pregnancy (ICP).

This is an open-label study where all participants will receive maralixibat.

Study Start Date: Jan. 15, 2027

Study Type: INTERVENTIONAL

Condition: Intrahepatic Cholestasis of Pregnancy

Intervention: DRUG: Maralixibat

Maralixibat tablets: 10 mg and 15 mg. Maralixibat oral solution 20 mg...